Vaxxinity jumps as Jefferies initiates coverage with 'buy' rating

Vaxxinity

07/12/2021 15:44

** Vaxxinity Inc's shares  VAXX.O  rise 19% to $8.70 - set
to snap fall in six straight sessions
    ** Brokerage Jefferies initiates coverage on VAXX with 'buy'
rating and PT of $18 on optimism over co's vaccine pipeline; PT
146% higher than Monday's closing price
    ** "VAXX's platform can turn the body into its own antibody
factory," brokerage says about co's vaccine technology that uses
synthetic peptides to activate the immune system
    ** VAXX's Alzheimer's vaccine has shown it can elicit
antibodies that bind to toxic amyloid-beta aggregates in the
brain - brokerage
    ** On Monday, Bank of America Global Research also initiated
coverage on stock with "buy" rating for a PT of $21
    ** VAXX shares down 33% from IPO price of $13; stock was
listed on Nov. 11

 (Reporting by Leroy Leo)
 ((Leroy.Dsouza@thomsonreuters.com;))